At a glance
ClinicalIndex Comparison RecordN/ACompleted· 414 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation
In Brief
An observational study for Ovarian Cancer. Completed, enrolled 414 participants across 24 sites.
Detailed Summary
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartJun 2023
First PostedJun 2023
Primary CompletionMay 2025
TodayJul 2026
First PostedJun 26, 2023
Enrollment StartJun 21, 2023
Primary CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.0 years ago